Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Shots: Shots:
- Teva and Celltrion launch Truxima (rituximab-abbs) to treat RA in combination with MTX in patients with mod.to sev. active RA who have an inadequate response to one or more TNF antagonist therapies and to treat GPA and MPA in combination with glucocorticoids
- Truxima has received CMS pass-through status in the hospital outpatient setting and is expected to be available at a WAC of $845.55/ 100mg and $4-227.75/ 500mg vial
- In Oct’2016- the two companies entered into an exclusive partnership- under which TEVA got commercializing right in the US and Canada. In May’2019- the US FDA approved Truxima for all approved indication of the reference product- Rituxan
Click here to read full press release/ article | Ref: PRNewswire | Image: Celltrion
Related News: Teva and Celltrion Reports the Availability of Truxima (biosimilar- Rituxan) in the US
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
